PMC:7127386 / 10488-10620 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"245","span":{"begin":95,"end":108},"obj":"Disease"}],"attributes":[{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"MESH:D012559"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T73","span":{"begin":95,"end":108},"obj":"Disease"}],"attributes":[{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0005090"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T162","span":{"begin":0,"end":28},"obj":"Chemical"},{"id":"T163","span":{"begin":0,"end":14},"obj":"Chemical"},{"id":"T164","span":{"begin":15,"end":28},"obj":"Chemical"},{"id":"T165","span":{"begin":29,"end":39},"obj":"Chemical"}],"attributes":[{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_3649"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_3647"},{"id":"A164","pred":"chebi_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}

{"project":"LitCovid-sentences","denotations":[{"id":"T70","span":{"begin":0,"end":132},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":95,"end":108},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0100753"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T75776","span":{"begin":60,"end":65},"obj":"NCBITaxon:10239"}],"text":"Chlorpromazine hydrochloride antagonist for post-synaptic receptors FDA approved treatment for schizophrenia 69-09-0 21.29 \u003e100 N.D."}